This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
by Zacks Equity Research
Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.
Is the Options Market Predicting a Spike in Shire (SHPG) Stock?
by Zacks Equity Research
Investors need to pay close attention to Shire (SHPG) stock based on the movements in the options market lately.
Shire's Takhzyro Gets European Nod for Hereditary Angioedema
by Zacks Equity Research
Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
Shire-Takeda Deal Gets Phase I Conditional European Approval
by Zacks Equity Research
Takeda's bid to acquire Shire (SHPG) receives conditional approval from the European Commission.
Shire's Filing Accepted by FDA for Gattex's Label Expansion
by Zacks Equity Research
The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.
Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3
by Zacks Equity Research
Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.
J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study
by Zacks Equity Research
J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study.
Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap
by Zacks Equity Research
Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.
Is Shire (SHPG) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Shire plc (SHPG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Company News For Sep 17, 2018
by Zacks Equity Research
Companies In The News are: ADBE,LB,NI,SHPG
Shire's ADHD Portfolio Remains Strong Amid Competition
by Zacks Equity Research
Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.
Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema
by Zacks Equity Research
Shire???s (SHPG) Takhzyro gets approval from the FDA for the treatment of hereditary angioedema in patients 12 years of age and older. It is the first-of-its-kind mAb preventive treatment for the same.
Shire, Shionogi File NDA for Intuniv for Adults in Japan
by Zacks Equity Research
Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
by Zacks Equity Research
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.
Company News For Jul 11, 2018
by Zacks Equity Research
Companies In The News are: SHPG,SJM,XRX,PCAR
Is Shire (SHPG) a Great Stock for Value Investors?
by Zacks Equity Research
Let's put Shire (SHPG) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population
by Zacks Equity Research
Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.
Allergan Requests Shareholders to Veto Management Change
by Zacks Equity Research
Allergan (AGN) responds to shareholders stating that it is open to the latter's opinions. However, the company has requested them to vote against appointment of independent chairman.
Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.
Should First Trust NASDAQ-100 Equal Weighted Index Fund (QQEW) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for QQEW
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.
Is First Trust NASDAQ-100 Equal Weighted Index Fund (QQEW) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for QQEW